These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 33512347)

  • 1. In Brief: Semglee - a new insulin glargine for diabetes.
    Med Lett Drugs Ther; 2021 Jan; 63(1616):14-15. PubMed ID: 33512347
    [No Abstract]   [Full Text] [Related]  

  • 2. In brief: Semglee - insulin glargine interchangeable with Lantus.
    Med Lett Drugs Ther; 2021 Oct; 63(1634):159-160. PubMed ID: 34550958
    [No Abstract]   [Full Text] [Related]  

  • 3. Concentrated insulin glargine (Toujeo) for diabetes.
    Med Lett Drugs Ther; 2015 May; 57(1468):69-70. PubMed ID: 25941955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Brief: Rezvoglar - another insulin glargine product interchangeable with Lantus.
    Med Lett Drugs Ther; 2023 Apr; 65(1673):56. PubMed ID: 37020341
    [No Abstract]   [Full Text] [Related]  

  • 5. A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia.
    Heller S; Mathieu C; Kapur R; Wolden ML; Zinman B
    Diabet Med; 2016 Apr; 33(4):478-87. PubMed ID: 26484727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes.
    Lamb YN; Syed YY
    BioDrugs; 2018 Feb; 32(1):91-98. PubMed ID: 29368288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin glargine and its place in the treatment of Types 1 and 2 diabetes mellitus.
    Chatterjee S; Tringham JR; Davies MJ
    Expert Opin Pharmacother; 2006 Jul; 7(10):1357-71. PubMed ID: 16805721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml.
    Steinstraesser A; Schmidt R; Bergmann K; Dahmen R; Becker RH
    Diabetes Obes Metab; 2014 Sep; 16(9):873-6. PubMed ID: 24571126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical experiences with Lantus therapy in Swedish routine health care].
    Löndahl M; Nilsson A; Katzman P
    Lakartidningen; 2005 Sep 5-11; 102(36):2503, 2505. PubMed ID: 16196437
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus.
    Ilag LL; Deeg MA; Costigan T; Hollander P; Blevins TC; Edelman SV; Konrad RJ; Ortmann RA; Pollom RK; Huster WJ; Zielonka JS; Prince MJ
    Diabetes Obes Metab; 2016 Feb; 18(2):159-68. PubMed ID: 26434665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Insulins and New Aspects in Insulin Delivery.
    Woo VC
    Can J Diabetes; 2015 Aug; 39(4):335-43. PubMed ID: 26233724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glargine and cancer: can we now suggest closure?
    Owens DR
    Diabetes Care; 2012 Dec; 35(12):2426-8. PubMed ID: 23173130
    [No Abstract]   [Full Text] [Related]  

  • 13. A Propensity Score Matched Comparison of Brand and Biosimilar Basal Insulin in Non-Critical Hospitalized Patients with Type 2 Diabetes Mellitus.
    Hu X; Zhang L; Dong C; Dong Y; Jiang J; Gao W
    Adv Ther; 2019 May; 36(5):1132-1142. PubMed ID: 30900200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New generation of insulins: glargine U300. Summary of clinical evidence].
    Musso C; Capurro L; Mingote E; Forti L; Guaita MS
    Medicina (B Aires); 2019; 79(4):241-250. PubMed ID: 31487242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark.
    Pollock RF; Tikkanen CK
    J Med Econ; 2017 Mar; 20(3):213-220. PubMed ID: 27705031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus.
    Blair HA; Keating GM
    Drugs; 2016 Mar; 76(3):363-74. PubMed ID: 26821280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin glargine: a systematic review of a long-acting insulin analogue.
    Wang F; Carabino JM; Vergara CM
    Clin Ther; 2003 Jun; 25(6):1541-77, discussion 1539-40. PubMed ID: 12860485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of basal supported oral therapy with insulin glargine, in Japanese insulin-naive, type 2 diabetes patients, with or without microvascular complications: subanalysis of the observational, non-interventional, 24-week follow-up Add-on Lantus® to Oral Hypoglycemic Agents (ALOHA) study.
    Odawara M; Kadowaki T; Naito Y
    J Diabetes Complications; 2015; 29(1):127-33. PubMed ID: 25449981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spotlight on insulin glargine in type 1 and 2 diabetes mellitus.
    McKeage K; Goa KL
    Treat Endocrinol; 2002; 1(1):55-8. PubMed ID: 15765621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of a needle-free injector in Chinese patients with type 2 diabetes mellitus treated with basal insulin: a multicentre, prospective, randomised, crossover study.
    Xing Y; Xie X; Xu J; Liu J; He Q; Yang W; Zhang N; Li X; Wang L; Fu J; Zhou J; Gao B; Ming J; Liu X; Lai J; Liu T; Shi M; Ji Q
    Expert Opin Drug Deliv; 2019 Sep; 16(9):995-1002. PubMed ID: 31359813
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.